A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation.

Eric Haas; Erol Onel; Howard Miller; Madhu Ragupathi; Paul F White

doi:10.1177/000313481207800540

A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation.

Eric Haas
, Erol Onel
, Howard Miller
, Madhu Ragupathi
, Paul F White

Colorectal Surgical Associates, Ltd, LLP, Houston, Texas, USA.
Pacira Pharmaceuticals, Inc., Parsippany, New Jersey;
The Woman's Hospital of Texas and Fannin Surgicare, Houston, Texas; and the, California
Colorectal Surgical Associates, Ltd, LLP, Houston, Texas;
Cedars-Sinai Medical Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	The American Surgeon
Volume	78
Issue number	5
DOIs	https://doi.org/10.1177/000313481207800540
State	Published - May 1 2012
Externally published	Yes

Disciplines

Medicine and Health Sciences
Anesthesiology

Access to Document

10.1177/000313481207800540License: Unspecified

Cite this

@article{0cdc27f566b844a397f5335609574ff7,

title = "A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation.",

author = "Eric Haas and Erol Onel and Howard Miller and Madhu Ragupathi and White, \{Paul F\}",

note = "This randomized, active-controlled study evaluated the extent and duration of analgesia after administration of liposome bupivacaine (LB), a novel formulation of bupivacaine, compared with bupivacaine HCl given via local infiltration in excisional hemorrhoidectomy. One hundred patients were randomly assigned to receive a single dose of bupivacaine HCl 75 mg (0.25\% with 1:200,000 epinephrine) or LB 66, 199, or 266 mg upon completion of hemorrhoidectomy.",

year = "2012",

month = may,

day = "1",

doi = "10.1177/000313481207800540",

language = "American English",

volume = "78",

journal = "The American Surgeon",

issn = "1555-9823",

publisher = "Sage",

number = "5",

}

TY - JOUR

T1 - A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation.

AU - Haas, Eric

AU - Onel, Erol

AU - Miller, Howard

AU - Ragupathi, Madhu

AU - White, Paul F

N1 - This randomized, active-controlled study evaluated the extent and duration of analgesia after administration of liposome bupivacaine (LB), a novel formulation of bupivacaine, compared with bupivacaine HCl given via local infiltration in excisional hemorrhoidectomy. One hundred patients were randomly assigned to receive a single dose of bupivacaine HCl 75 mg (0.25% with 1:200,000 epinephrine) or LB 66, 199, or 266 mg upon completion of hemorrhoidectomy.

PY - 2012/5/1

Y1 - 2012/5/1

UR - https://journals.sagepub.com/doi/pdf/10.1177/000313481207800540

U2 - 10.1177/000313481207800540

DO - 10.1177/000313481207800540

M3 - Article

SN - 1555-9823

VL - 78

JO - The American Surgeon

JF - The American Surgeon

IS - 5

ER -

A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation.

Disciplines

Access to Document

Other files and links

Cite this